Yale Head and Neck SPORE Publications

2024

Molecular Genetics Augment Cytopathologic Evaluation and Surgical Planning of Pediatric Thyroid Nodules.Spaulding SL, Maayah M, Dinauer CA, Prasad M, Darbinyan A, Morotti R, Christison-Lagay ER. J Pediatr Surg. 2024 May; 2024 Jan 7. PMID: 38246817.
In Vivo Verification of Electron Paramagnetic Resonance Biodosimetry Using Patients Undergoing Radiation Therapy Treatment.Draeger E, Roberts K, Decker RD, Bahar N, Wilson LD, Contessa J, Husain Z, Williams BB, Flood AB, Swartz HM, Carlson DJ. Int J Radiat Oncol Biol Phys. 2024 May 1; 2023 Dec 10. PMID: 38072322.
Identifying Opportunities to Deliver High-Quality Cancer Care Across a Health System: A Clinical Responsibility.Shah HP, Cohen O, Bourdillon AT, Burtness BA, Boffa DJ, Young M, Judson BL, Mehra S. Otolaryngol Head Neck Surg. 2024 Apr 12; 2024 Apr 12. PMID: 38606669.
Essential data variables for a minimum dataset for head and neck cancer trials and clinical research: HNCIG consensus recommendations and database.Baliga S, Abou-Foul AK, Parente P, Szturz P, Thariat J, Shreenivas A, Nankivell P, Bertolini F, Biau J, Blakaj D, Brennan S, Brunet A, De Oliveira TB, Burtness B, Maseda AC, Chow VL, Chua ML, de Ridder M, Garikipati S, Hanai N, Ho FCH, Huang SH, Kiyota N, Klinghammer K, Kowalski LP, Kwong DL, McDowell LJ, Merlano MC, Nair S, Economopoulou P, Overgaard J, Psyrri A, Tribius S, Waldron J, Yom SS, Mehanna H. Eur J Cancer. 2024 Mar 30; 2024 Mar 30. PMID: 38579517.
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial.Machiels JP, Tao Y, Licitra L, Burtness B, Tahara M, Rischin D, Alves G, Lima IPF, Hughes BGM, Pointreau Y, Aksoy S, Laban S, Greil R, Burian M, Hetnał M, Delord JP, Mesía R, Taberna M, Waldron JN, Simon C, Grégoire V, Harrington KJ, Swaby RF, Zhang Y, Gumuscu B, Bidadi B, Siu LL. Lancet Oncol. 2024 Mar 29; 2024 Mar 29. PMID: 38561010.
An algorithm for standardization of tumor Infiltrating lymphocyte evaluation in head and neck cancers.Xirou V, Moutafi M, Bai Y, Nwe Aung T, Burela S, Liu M, Kimple RJ, Shabbir Ahmed F, Schultz B, Flieder D, Connolly DC, Psyrri A, Burtness B, Rimm DL. Oral Oncol. 2024 Mar 27; 2024 Mar 27. PMID: 38547779.
Digital spatial proteomic profiling reveals immune checkpoints as biomarkers in lymphoid aggregates and tumor microenvironment of desmoplastic melanoma.Su DG, Schoenfeld DA, Ibrahim W, Cabrejo R, Djureinovic D, Baumann R, Rimm DL, Khan SA, Halaban R, Kluger HM, Olino K, Galan A, Clune J. J Immunother Cancer. 2024 Mar 21; 2024 Mar 21. PMID: 38519058.
Impact of (18)F-FDG PET Intensity Normalization on Radiomic Features of Oropharyngeal Squamous Cell Carcinomas and Machine Learning-Generated Biomarkers.Haider SP, Zeevi T, Sharaf K, Gross M, Mahajan A, Kann BH, Judson BL, Prasad ML, Burtness B, Aboian M, Canis M, Reichel CA, Baumeister P, Payabvash S. J Nucl Med. 2024 Mar 21; 2024 Mar 21. PMID: 38514087.
The role of surgery and deescalation for HPV-related oropharyngeal cancer.Contrera KJ, Patel MR, Burtness B, Mehra R, Ferris RL. Cancer. 2024 Mar 18; 2024 Mar 18. PMID: 38497569.
Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients.Brahmer JR, Long GV, Hamid O, Garon EB, Herbst RS, Andre T, Armand P, Bajorin D, Bellmunt J, Burtness B, Choueiri TK, Cohen EEW, Diaz LA Jr, Shitara K, Kulkarni G, McDermott D, Shah M, Tabernero J, Vogel A, Zinzani PL, Jafari N, Bird S, Snyder E, Gause C, Bracco OL, Pietanza MC, Gruber T, Ribas A. Eur J Cancer. 2024 Mar; 2024 Jan 11. PMID: 38295556.
Image-based multiplex immune profiling of cancer tissues: translational implications. A report of the International Immuno-oncology Biomarker Working Group on Breast Cancer.Jahangir CA, Page DB, Broeckx G, Gonzalez CA, Burke C, Murphy C, Reis-Filho JS, Ly A, Harms PW, Gupta RR, Vieth M, Hida AI, Kahila M, Kos Z, van Diest PJ, Verbandt S, Thagaard J, Khiroya R, Abduljabbar K, Acosta Haab G, Acs B, Adams S, Almeida JS, Alvarado-Cabrero I, Azmoudeh-Ardalan F, Badve S, Baharun NB, Bellolio ER, Bheemaraju V, Blenman KR, Botinelly Mendonça Fujimoto L, Burgues O, Chardas A, Cheang MCU, Ciompi F, Cooper LA, Coosemans A, Corredor G, Dantas Portela FL, Deman F, Demaria S, Dudgeon SN, Elghazawy M, Fernandez-Martín C, Fineberg S, Fox SB, Giltnane JM, Gnjatic S, Gonzalez-Ericsson PI, Grigoriadis A, Halama N, Hanna MG, Harbhajanka A, Hart SN, Hartman J, Hewitt S, Horlings HM, Husain Z, Irshad S, Janssen EA, Kataoka TR, Kawaguchi K, Khramtsov AI, Kiraz U, Kirtani P, Kodach LL, Korski K, Akturk G, Scott E, Kovács A, Laenkholm AV, Lang-Schwarz C, Larsimont D, Lennerz JK, Lerousseau M, Li X, Madabhushi A, Maley SK, Manur Narasimhamurthy V, Marks DK, McDonald ES, Mehrotra R, Michiels S, Kharidehal D, Minhas FUAA, Mittal S, Moore DA, Mushtaq S, Nighat H, Papathomas T, Penault-Llorca F, Perera RD, Pinard CJ, Pinto-Cardenas JC, Pruneri G, Pusztai L, Rajpoot NM, Rapoport BL, Rau TT, Ribeiro JM, Rimm D, Vincent-Salomon A, Saltz J, Sayed S, Hytopoulos E, Mahon S, Siziopikou KP, Sotiriou C, Stenzinger A, Sughayer MA, Sur D, Symmans F, Tanaka S, Taxter T, Tejpar S, Teuwen J, Thompson EA, Tramm T, Tran WT, van der Laak J, Verghese GE, Viale G, Wahab N, Walter T, Waumans Y, Wen HY, Yang W, Yuan Y, Bartlett J, Loibl S, Denkert C, Savas P, Loi S, Specht Stovgaard E, Salgado R, Gallagher WM, Rahman A. J Pathol. 2024 Mar; 2024 Jan 17. PMID: 38230434.
High-Plex Assessment of Biomarkers in Tumors.Aung TN, Bates KM, Rimm DL. Mod Pathol. 2024 Mar; 2024 Jan 12. PMID: 38219953.
A new prognostic model in chemotherapy-treated patients with recurrent or metastatic head and neck cancer: An analysis of ECOG-ACRIN E1305.Argiris A, Flamand Y, Savvides P, Johnson JM, Vathiotis I, Levine M, Li S, Forastiere AA, Burtness B. Eur J Cancer. 2024 Mar; 2023 Dec 29. PMID: 38215573.
Multiplexable and Scalable Aqueous Synthesis Platform for Oleate-Based, Bilayer-Coated Gold Nanoparticles.Backhaus A, Albrecht J, Alzhanova G, Long A, Arnold W, Lee J, Tse HY, Su TT, Cruz-Gomez S, Lee SSS, Menges F, Parent LR, Ratjen L, Burtness B, Fortner JD, Zimmerman JB. Small. 2024 Feb 20; 2024 Feb 20. PMID: 38377304.
Correlation of HER2 Protein Level With mRNA Level Quantified by RNAscope in Breast Cancer.Li X, Lee JH, Gao Y, Zhang J, Bates KM, Rimm DL, Zhang H, Smith GH, Lawson D, Meisel J, Chang J, Huo L. Mod Pathol. 2024 Feb; 2023 Dec 20. PMID: 38135153.
Automated scoring of tumor-infiltrating lymphocytes informs risk of death from thin melanoma: A nested case-case study.Tan SX, Aung TN, Claeson M, Acs B, Zhou C, Brown S, Lambie D, Baade PD, Pandeya N, Soyer HP, Smithers BM, Whiteman DC, Rimm DL, Khosrotehrani K. J Am Acad Dermatol. 2024 Jan; 2023 Sep 19. PMID: 37730017.

2023

ER chaperones use a protein folding and quality control glyco-code.Guay KP, Ke H, Canniff NP, George GT, Eyles SJ, Mariappan M, Contessa JN, Gershenson A, Gierasch LM, Hebert DN. Mol Cell. 2023 Dec 21; 2023 Dec 4. PMID: 38052210.
A Novel Saliva and Serum miRNA Panel as a Potential Useful Index for Oral Cancer and the Association of miR-21 with Smoking History: a Pilot Study.Vageli DP, Doukas PG, Shah R, Boyi T, Liu C, Judson BL. Cancer Prev Res (Phila). 2023 Dec 1. PMID: 37683274.
Association of Age and Frailty With 30-Day Outcomes Among Patients Undergoing Oral Cavity Cancer Surgery.Boyi T, Williams LC, Kafle S, Roche AM, Judson BL. Otolaryngol Head Neck Surg. 2023 Dec; 2023 Aug 18. PMID: 37595108.
Over-The-Counter Hearing Aids: Trends in Information-Seeking Behavior.Panth N, Shah R, Judson B, Schwartz N. Otolaryngol Head Neck Surg. 2023 Dec; 2023 Jun 27. PMID: 37365970.
Improving Post-procedure Outcomes With Clinical Care Pathway for Enteral Access.Miller SM, Abou-Azar S, Owusu KA, Judson BL, Rhodes D, Morton JM. Am Surg. 2023 Dec; 2023 May 19. PMID: 37203186.
Emerging Prognostic and Predictive Significance of Stress Keratin 17 in HPV-Associated and Non HPV-Associated Human Cancers: A Scoping Review.Lozar T, Wang W, Gavrielatou N, Christensen L, Lambert PF, Harari PM, Rimm DL, Burtness B, Grasic Kuhar C, Carchman EH. Viruses. 2023 Nov 25; 2023 Nov 25. PMID: 38140561.
Radiotherapy Plus Cisplatin With or Without Lapatinib for Non-Human Papillomavirus Head and Neck Carcinoma: A Phase 2 Randomized Clinical Trial.Wong SJ, Torres-Saavedra PA, Saba NF, Shenouda G, Bumpous JM, Wallace RE, Chung CH, El-Naggar AK, Gwede CK, Burtness B, Tennant PA, Dunlap NE, Redman R, Stokes WA, Rudra S, Mell LK, Sacco AG, Spencer SA, Nabell L, Yao M, Cury FL, Mitchell DL, Jones CU, Firat S, Contessa JN, Galloway T, Currey A, Harris J, Curran WJ Jr, Le QT. JAMA Oncol. 2023 Nov 1. PMID: 37768670.
Extra imaging beyond NCCN surveillance guidelines is cost effective for HPV- but not HPV+ oropharyngeal cancer.Shah R, Tyagi S, Liu C, Judson B. Oral Oncol. 2023 Nov; 2023 Sep 4. PMID: 37672950.
The Representation of Surgery in Oncology Clinical Trials: 2001 to 2022.Shah R, Boffa D, Khan S, Judson B. Ann Surg Oncol. 2023 Nov; 2023 Aug 9. PMID: 37556010.
Stress Keratin 17 Is a Predictive Biomarker Inversely Associated with Response to Immune Check-Point Blockade in Head and Neck Squamous Cell Carcinomas and Beyond.Lozar T, Laklouk I, Golfinos AE, Gavrielatou N, Xu J, Flynn C, Keske A, Yu M, Bruce JY, Wang W, Grasic Kuhar C, Bailey HH, Harari PM, Dinh HQ, Rimm DL, Hu R, Lambert PF, Fitzpatrick MB. Cancers (Basel). 2023 Oct 9; 2023 Oct 9. PMID: 37835599.
The room where it happens: addressing diversity, equity, and inclusion in National Clinical Trials Network clinical trial leadership.Snyder RA, Burtness B, Cho M, Del Rivero J, Doroshow DB, Hitchcock KE, Kalyan A, Kim CA, Lukovic J, Parikh AR, Sanford NN, Singh B, Shen C, Shroff RT, Vijayvergia N, Goodman KA, Kunz PL. J Natl Cancer Inst. 2023 Oct 9. PMID: 37364007.
Digital spatial profiling of melanoma shows CD95 expression in immune cells is associated with resistance to immunotherapy.Martinez-Morilla S, Moutafi M, Fernandez AI, Jessel S, Divakar P, Wong PF, Garcia-Milian R, Schalper KA, Kluger HM, Rimm DL. Oncoimmunology. 2023; 2023 Sep 27. PMID: 37781235.
Paclitaxel With or Without Cixutumumab as Second-Line Treatment of Metastatic Esophageal or Gastroesophageal Junction Cancer: A Randomized Phase II ECOG-ACRIN Trial.Stockton S, Catalano P, Cohen SJ, Burtness BA, Mitchell EP, Dotan E, Lubner SJ, Kumar P, Mulcahy MF, Fisher GA, Crandall TL, Benson A. Oncologist. 2023 Sep 7. PMID: 37104870.
Classification of Breast Cancer According to ERBB2 Immunohistochemistry Scores.Robbins CJ, Fernandez AI, Rimm DL. JAMA Oncol. 2023 Sep 1. PMID: 37498606.
Mammalian SWI/SNF chromatin remodeling complexes promote tyrosine kinase inhibitor resistance in EGFR-mutant lung cancer.de Miguel FJ, Gentile C, Feng WW, Silva SJ, Sankar A, Exposito F, Cai WL, Melnick MA, Robles-Oteiza C, Hinkley MM, Tsai JA, Hartley AV, Wei J, Wurtz A, Li F, Toki MI, Rimm DL, Homer R, Wilen CB, Xiao AZ, Qi J, Yan Q, Nguyen DX, Jänne PA, Kadoch C, Politi KA. Cancer Cell. 2023 Aug 14; 2023 Aug 3. PMID: 37541244.
Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer.Moutafi M, Koliou GA, Papaxoinis G, Economopoulou P, Kotsantis I, Gkotzamanidou M, Anastasiou M, Pectasides D, Kyrodimos E, Delides A, Giotakis E, Papadimitriou NG, Panayiotides IG, Perisanidis C, Fernandez AI, Xirou V, Poulios C, Gagari E, Yaghoobi V, Gavrielatou N, Shafi S, Aung TN, Kougioumtzopoulou A, Kouloulias V, Palialexis K, Gkolfinopoulos S, Strati A, Lianidou E, Fountzilas G, Rimm DL, Foukas PG, Psyrri A. Cancer Res Commun. 2023 Aug; 2023 Aug 10. PMID: 37575280.
Noncanonical HPV carcinogenesis drives radiosensitization of head and neck tumors.Schrank TP, Kothari A, Weir WH, Stepp WH, Rehmani H, Liu X, Wang X, Sewell A, Li X, Tasoulas J, Kim S, Yarbrough G, Xie Y, Flamand Y, Marur S, Hayward MC, Wu D, Burtness B, Anderson KS, Baldwin AS, Yarbrough WG, Issaeva N. Proc Natl Acad Sci U S A. 2023 Aug 8; 2023 Jul 31. PMID: 37523561.
Prognostic value of absolute lymphocyte count in oral cavity squamous cell carcinoma.Shah R, Liu C, Shah HP, Judson BL. Laryngoscope Investig Otolaryngol. 2023 Aug; 2023 Jun 15. PMID: 37621277.
Pitfalls in machine learning-based assessment of tumor-infiltrating lymphocytes in breast cancer: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer.Thagaard J, Broeckx G, Page DB, Jahangir CA, Verbandt S, Kos Z, Gupta R, Khiroya R, Abduljabbar K, Acosta Haab G, Acs B, Akturk G, Almeida JS, Alvarado-Cabrero I, Amgad M, Azmoudeh-Ardalan F, Badve S, Baharun NB, Balslev E, Bellolio ER, Bheemaraju V, Blenman KR, Botinelly Mendonça Fujimoto L, Bouchmaa N, Burgues O, Chardas A, Chon U Cheang M, Ciompi F, Cooper LA, Coosemans A, Corredor G, Dahl AB, Dantas Portela FL, Deman F, Demaria S, Doré Hansen J, Dudgeon SN, Ebstrup T, Elghazawy M, Fernandez-Martín C, Fox SB, Gallagher WM, Giltnane JM, Gnjatic S, Gonzalez-Ericsson PI, Grigoriadis A, Halama N, Hanna MG, Harbhajanka A, Hart SN, Hartman J, Hauberg S, Hewitt S, Hida AI, Horlings HM, Husain Z, Hytopoulos E, Irshad S, Janssen EA, Kahila M, Kataoka TR, Kawaguchi K, Kharidehal D, Khramtsov AI, Kiraz U, Kirtani P, Kodach LL, Korski K, Kovács A, Laenkholm AV, Lang-Schwarz C, Larsimont D, Lennerz JK, Lerousseau M, Li X, Ly A, Madabhushi A, Maley SK, Manur Narasimhamurthy V, Marks DK, McDonald ES, Mehrotra R, Michiels S, Minhas FUAA, Mittal S, Moore DA, Mushtaq S, Nighat H, Papathomas T, Penault-Llorca F, Perera RD, Pinard CJ, Pinto-Cardenas JC, Pruneri G, Pusztai L, Rahman A, Rajpoot NM, Rapoport BL, Rau TT, Reis-Filho JS, Ribeiro JM, Rimm D, Roslind A, Vincent-Salomon A, Salto-Tellez M, Saltz J, Sayed S, Scott E, Siziopikou KP, Sotiriou C, Stenzinger A, Sughayer MA, Sur D, Fineberg S, Symmans F, Tanaka S, Taxter T, Tejpar S, Teuwen J, Thompson EA, Tramm T, Tran WT, van der Laak J, van Diest PJ, Verghese GE, Viale G, Vieth M, Wahab N, Walter T, Waumans Y, Wen HY, Yang W, Yuan Y, Zin RM, Adams S, Bartlett J, Loibl S, Denkert C, Savas P, Loi S, Salgado R, Specht Stovgaard E. J Pathol. 2023 Aug; 2023 Aug 23. PMID: 37608772.
Spatial analyses of immune cell infiltration in cancer: current methods and future directions: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer.Page DB, Broeckx G, Jahangir CA, Verbandt S, Gupta RR, Thagaard J, Khiroya R, Kos Z, Abduljabbar K, Acosta Haab G, Acs B, Akturk G, Almeida JS, Alvarado-Cabrero I, Azmoudeh-Ardalan F, Badve S, Baharun NB, Bellolio ER, Bheemaraju V, Blenman KR, Botinelly Mendonça Fujimoto L, Bouchmaa N, Burgues O, Cheang MCU, Ciompi F, Cooper LA, Coosemans A, Corredor G, Dantas Portela FL, Deman F, Demaria S, Dudgeon SN, Elghazawy M, Ely S, Fernandez-Martín C, Fineberg S, Fox SB, Gallagher WM, Giltnane JM, Gnjatic S, Gonzalez-Ericsson PI, Grigoriadis A, Halama N, Hanna MG, Harbhajanka A, Hardas A, Hart SN, Hartman J, Hewitt S, Hida AI, Horlings HM, Husain Z, Hytopoulos E, Irshad S, Janssen EA, Kahila M, Kataoka TR, Kawaguchi K, Kharidehal D, Khramtsov AI, Kiraz U, Kirtani P, Kodach LL, Korski K, Kovács A, Laenkholm AV, Lang-Schwarz C, Larsimont D, Lennerz JK, Lerousseau M, Li X, Ly A, Madabhushi A, Maley SK, Manur Narasimhamurthy V, Marks DK, McDonald ES, Mehrotra R, Michiels S, Minhas FUAA, Mittal S, Moore DA, Mushtaq S, Nighat H, Papathomas T, Penault-Llorca F, Perera RD, Pinard CJ, Pinto-Cardenas JC, Pruneri G, Pusztai L, Rahman A, Rajpoot NM, Rapoport BL, Rau TT, Reis-Filho JS, Ribeiro JM, Rimm D, Vincent-Salomon A, Salto-Tellez M, Saltz J, Sayed S, Siziopikou KP, Sotiriou C, Stenzinger A, Sughayer MA, Sur D, Symmans F, Tanaka S, Taxter T, Tejpar S, Teuwen J, Thompson EA, Tramm T, Tran WT, van der Laak J, van Diest PJ, Verghese GE, Viale G, Vieth M, Wahab N, Walter T, Waumans Y, Wen HY, Yang W, Yuan Y, Adams S, Bartlett JMS, Loibl S, Denkert C, Savas P, Loi S, Salgado R, Specht Stovgaard E. J Pathol. 2023 Aug; 2023 Aug 23. PMID: 37608771.
Immune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressive stages of renal cell carcinoma and in brain metastases.Schoenfeld DA, Moutafi M, Martinez S, Djureinovic D, Merkin RD, Adeniran A, Braun DA, Signoretti S, Choueiri TK, Parisi F, Hurwitz M, Rimm DL, Wei W, Jilaveanu L, Kluger HM. J Immunother Cancer. 2023 Aug. PMID: 37586773.
Subsets of IFN Signaling Predict Response to Immune Checkpoint Blockade in Patients with Melanoma.Horowitch B, Lee DY, Ding M, Martinez-Morilla S, Aung TN, Ouerghi F, Wang X, Wei W, Damsky W, Sznol M, Kluger H, Rimm DL, Ishizuka JJ. Clin Cancer Res. 2023 Aug 1. PMID: 37233452.
Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer.Bauman JE, Saba NF, Roe D, Bauman JR, Kaczmar J, Bhatia A, Muzaffar J, Julian R, Wang S, Bearelly S, Baker A, Steuer C, Giri A, Burtness B, Centuori S, Caulin C, Klein R, Saboda K, Obara S, Chung CH. J Clin Oncol. 2023 Aug 1; 2023 Mar 28. PMID: 36977289.
Trends in Residency Applicant Volume in Otolaryngology-Head and Neck Surgery and Peer Specialties.Bourdillon AT, Salehi PP, Wride M, Salehi P, Torabi S, Heiser A, Shah HP, Azizzadeh B, Judson B, Lee YH. Ann Otol Rhinol Laryngol. 2023 Aug; 2022 Aug 29. PMID: 36031814.
Autologous humanized PDX modeling for immuno-oncology recapitulates features of the human tumor microenvironment.Chiorazzi M, Martinek J, Krasnick B, Zheng Y, Robbins KJ, Qu R, Kaufmann G, Skidmore Z, Juric M, Henze LA, Brösecke F, Adonyi A, Zhao J, Shan L, Sefik E, Mudd J, Bi Y, Goedegebuure SP, Griffith M, Griffith O, Oyedeji A, Fertuzinhos S, Garcia-Milian R, Boffa D, Detterbeck F, Dhanasopon A, Blasberg J, Judson B, Gettinger S, Politi K, Kluger Y, Palucka K, Fields RC, Flavell RA. J Immunother Cancer. 2023 Jul. PMID: 37487666.
Deep learning-based scoring of tumour-infiltrating lymphocytes is prognostic in primary melanoma and predictive to PD-1 checkpoint inhibition in melanoma metastases.Chatziioannou E, Roßner J, Aung TN, Rimm DL, Niessner H, Keim U, Serna-Higuita LM, Bonzheim I, Kuhn Cuellar L, Westphal D, Steininger J, Meier F, Pop OT, Forchhammer S, Flatz L, Eigentler T, Garbe C, Röcken M, Amaral T, Sinnberg T. EBioMedicine. 2023 Jul; 2023 Jun 7. PMID: 37295047.
Multiplex Immunohistochemistry and Immunofluorescence: A Practical Update for Pathologists.Harms PW, Frankel TL, Moutafi M, Rao A, Rimm DL, Taube JM, Thomas D, Chan MP, Pantanowitz L. Mod Pathol. 2023 Jul; 2023 Apr 25. PMID: 37105494.
Tissue Age Affects Antigenicity and Scoring for the 22C3 Immunohistochemistry Companion Diagnostic Test.Fernandez AI, Gaule P, Rimm DL. Mod Pathol. 2023 Jul; 2023 Mar 15. PMID: 36925070.
Deep computational image analysis of immune cell niches reveals treatment-specific outcome associations in lung cancer.Barrera C, Corredor G, Viswanathan VS, Ding R, Toro P, Fu P, Buzzy C, Lu C, Velu P, Zens P, Berezowska S, Belete M, Balli D, Chang H, Baxi V, Syrigos K, Rimm DL, Velcheti V, Schalper K, Romero E, Madabhushi A. NPJ Precis Oncol. 2023 Jun 1; 2023 Jun 1. PMID: 37264091.
Evaluating the medical management of locally advanced and metastatic basal cell carcinoma: A single institutional retrospective analysis investigating efficacy, safety, and tolerability.Belzer A, Pach J, Mortlock RD, Clune J, Olino K, Sznol M, Bhatia A, Burtness B, Christensen S, Leventhal JS. JAAD Int. 2023 Jun; 2023 Feb 26. PMID: 37252181.
Screening for extranodal extension in HPV-associated oropharyngeal carcinoma: evaluation of a CT-based deep learning algorithm in patient data from a multicentre, randomised de-escalation trial.Kann BH, Likitlersuang J, Bontempi D, Ye Z, Aneja S, Bakst R, Kelly HR, Juliano AF, Payabvash S, Guenette JP, Uppaluri R, Margalit DN, Schoenfeld JD, Tishler RB, Haddad R, Aerts HJWL, Garcia JJ, Flamand Y, Subramaniam RM, Burtness BA, Ferris RL. Lancet Digit Health. 2023 Jun; 2023 Apr 21. PMID: 37087370.
Grading system for medullary thyroid carcinoma; an institutional experience.Podany P, Meiklejohn K, Garritano J, Holt EH, Barbieri A, Prasad M, Gilani SM. Ann Diagn Pathol. 2023 Jun; 2023 Jan 31. PMID: 36736129.
Image analysis-based tumor infiltrating lymphocytes measurement predicts breast cancer pathologic complete response in SWOG S0800 neoadjuvant chemotherapy trial.Fanucci KA, Bai Y, Pelekanou V, Nahleh ZA, Shafi S, Burela S, Barlow WE, Sharma P, Thompson AM, Godwin AK, Rimm DL, Hortobagyi GN, Liu Y, Wang L, Wei W, Pusztai L, Blenman KRM. NPJ Breast Cancer. 2023 May 13; 2023 May 13. PMID: 37179362.
Assessment of the Impact of Alternative Fixatives on HER2 Detection in Breast Cancer and Gastric Cancer Tumor Specimens.Feng W, Inoue R, Kuwata T, Niikura N, Fujii S, Kumaki N, Honda K, Xu LA, Goetz A, Gaule P, Cogswell J, Rimm DL, McGee R. Appl Immunohistochem Mol Morphol. 2023 May-Jun 01; 2023 Apr 24. PMID: 37093713.
Multi-Institutional Study of Pathologist Reading of the Programmed Cell Death Ligand-1 Combined Positive Score Immunohistochemistry Assay for Gastric or Gastroesophageal Junction Cancer.Fernandez AI, Robbins CJ, Gaule P, Agostini-Vulaj D, Anders RA, Bellizzi AM, Chen W, Chen ZE, Gopal P, Zhao L, Lisovsky M, Liu X, Shia J, Wang H, Yang Z, McCann L, Chan YG, Weidler J, Bates M, Zhang X, Rimm DL. Mod Pathol. 2023 May; 2023 Feb 13. PMID: 36889057.
Diagnosis of acinic cell carcinoma of the salivary gland on cytology specimens: Role of NOR-1 (NR4A3) immunohistochemistry.Meiklejohn K, Hrones M, Wang M, Prasad ML, Cai G, Adeniran A, Gilani SM. Cytopathology. 2023 May; 2023 Mar 8. PMID: 36825365.
Top advances of the year: Head and neck cancer.Verma A, Burtness B. Cancer. 2023 May 1; 2023 Jan 24. PMID: 36692372.
The Role of PARP-1 and NF-κB in Bile-Induced DNA Damage and Oncogenic Profile in Hypopharyngeal Cells.Doukas PG, Vageli DP, Judson BL. Laryngoscope. 2023 May; 2022 Jul 6. PMID: 35791892.
First-Line Nivolumab Plus Ipilimumab in Recurrent/Metastatic Head and Neck Cancer-What Happened?Burtness B. J Clin Oncol. 2023 Apr 20; 2023 Mar 6. PMID: 36877893.
Human Immunodeficiency Virus Is Associated With Poor Overall Survival Among Patients With Head and Neck Cancer.Salahuddin S, Cohen O, Wu M, Perez Irizarry J, Vega T, Gan G, Deng Y, Isaeva N, Prasad M, Schalper KA, Mehra S, Yarbrough WG, Emu B. Clin Infect Dis. 2023 Apr 17. PMID: 36520995.
Digital Spatial Profiling Links Beta-2-microglobulin Expression with Immune Checkpoint Blockade Outcomes in Head and Neck Squamous Cell Carcinoma.Gavrielatou N, Vathiotis I, Aung TN, Shafi S, Burela S, Fernandez AI, Moutafi M, Burtness B, Economopoulou P, Anastasiou M, Foukas P, Psyrri A, Rimm DL. Cancer Res Commun. 2023 Apr; 2023 Apr 11. PMID: 37057033.
Outcomes Stratification of Head and Neck Cancer Using Pre- and Post-treatment DNA Methylation From Peripheral Blood.Qian DC, Ulrich BC, Peng G, Zhao H, Conneely KN, Miller AH, Bruner DW, Eldridge RC, Wommack EC, Higgins KA, Shin DM, Saba NF, Smith AK, Burtness B, Park HS, Stokes WA, Beitler JJ, Xiao C. Int J Radiat Oncol Biol Phys. 2023 Apr 1; 2022 Nov 21. PMID: 36410685.
Quantitative, Spatially Defined Expression of Leukocyte-associated Immunoglobulin-like Receptor in Non-small Cell Lung Cancer.Aung TN, Gavrielatou N, Vathiotis IA, Fernandez AI, Shafi S, Yaghoobi V, Burela S, MacNeil T, Ahmed FS, Myint H, Flies DB, Langermann S, Rimm DL. Cancer Res Commun. 2023 Mar; 2023 Mar 21. PMID: 36960400.
Signal recognition particle receptor-β (SR-β) coordinates cotranslational N-glycosylation.Phoomak C, Rinis N, Baro M, Shrimal S, Bennett D, Shaffer SA, Lehrman M, Gilmore R, Contessa JN. Sci Adv. 2023 Mar 17; 2023 Mar 15. PMID: 36921042.
Spatial characterization and quantification of CD40 expression across cancer types.Bates KM, Vathiotis I, MacNeil T, Ahmed FS, Aung TN, Katlinskaya Y, Bhattacharya S, Psyrri A, Yea S, Parkes A, Sadraei NH, Roychoudhury S, Rimm DL, Gavrielatou N. BMC Cancer. 2023 Mar 9; 2023 Mar 9. PMID: 36894898.
Impact of radiotherapy delay following biopsy for patients with unresected glioblastoma.Gao S, Jin L, Moliterno J, Corbin ZA, Bindra RS, Contessa JN, Yu JB, Park HS. J Neurosurg. 2023 Mar 1; 2022 Jul 29. PMID: 35907197.
Treating Head and Neck Cancer in the Age of Immunotherapy: A 2023 Update.Bhatia A, Burtness B. Drugs. 2023 Feb; 2023 Jan 16. PMID: 36645621.
Multicenter analysis of stereotactic radiosurgery for multiple brain metastases from EGFR and ALK driven non-small cell lung cancer.Wandrey NE, Gao D, Robin TP, Contessa JN, Singh C, Chiang V, Li J, Chen A, Wang Y, Sheehan JP, Dutta SW, Weiss SE, Paly J, Rusthoven CG. Lung Cancer. 2023 Feb; 2022 Dec 12. PMID: 36641932.
Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study.Harrington KJ, Burtness B, Greil R, Soulières D, Tahara M, de Castro G Jr, Psyrri A, Brana I, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesia R, Ngamphaiboon N, Rordorf T, Wan Ishak WZ, Lin J, Gumuscu B, Swaby RF, Rischin D. J Clin Oncol. 2023 Feb 1; 2022 Oct 11. PMID: 36219809.
Resident Burnout and Well-being in Otolaryngology and Other Surgical Specialties: Strategies for Change.Shah HP, Salehi PP, Ihnat J, Kim DD, Salehi P, Judson BL, Azizzadeh B, Lee YH. Otolaryngol Head Neck Surg. 2023 Feb. PMID: 35133919.
Author Correction: Head and neck squamous cell carcinoma.Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. Nat Rev Dis Primers. 2023 Jan 19; 2023 Jan 19. PMID: 36658129.
Multi-institutional Assessment of Pathologist Scoring HER2 Immunohistochemistry.Robbins CJ, Fernandez AI, Han G, Wong S, Harigopal M, Podoll M, Singh K, Ly A, Kuba MG, Wen H, Sanders MA, Brock J, Wei S, Fadare O, Hanley K, Jorns J, Snir OL, Yoon E, Rabe K, Soong TR, Reisenbichler ES, Rimm DL. Mod Pathol. 2023 Jan. PMID: 36788069.
The Pathologists' Conundrum.Rimm DL, Dacic S, Schnitt SJ. Arch Pathol Lab Med. 2023 Jan 1. PMID: 36577091.
An Algorithm as a Biomarker for Response to Immune Checkpoint Inhibitor Therapy.Rimm DL. JAMA Oncol. 2023 Jan 1. PMID: 36394848.

2022

Phase II Study of Enzalutamide for Patients With Androgen Receptor-Positive Salivary Gland Cancers (Alliance A091404).Ho AL, Foster NR, Zoroufy AJ, Campbell JD, Worden F, Price K, Adkins D, Bowles DW, Kang H, Burtness B, Sherman E, Morton R, Morris LGT, Nadeem Z, Katabi N, Munster P, Schwartz GK. J Clin Oncol. 2022 Dec 20; 2022 Jul 22. PMID: 35867947.
Baseline gene expression profiling determines long-term benefit to programmed cell death protein 1 axis blockade.Vathiotis IA, Salichos L, Martinez-Morilla S, Gavrielatou N, Aung TN, Shafi S, Wong PF, Jessel S, Kluger HM, Syrigos KN, Warren S, Gerstein M, Rimm DL. NPJ Precis Oncol. 2022 Dec 15; 2022 Dec 15. PMID: 36522538.
Clinical Trial Development in TP53-Mutated Locally Advanced and Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma.Rodriguez CP, Kang H, Geiger JL, Burtness B, Chung CH, Pickering CR, Fakhry C, Le QT, Yom SS, Galloway TJ, Golemis E, Li A, Shoop J, Wong S, Mehra R, Skinner H, Saba NF, Flores ER, Myers JN, Ford JM, Karchin R, Ferris RL, Kunos C, Lynn JM, Malik S. J Natl Cancer Inst. 2022 Dec 8. PMID: 36053203.
Methodologic Concerns in Secondary Analysis of KEYNOTE-048.Burtness B, Lin J, Souliéres D. JAMA Oncol. 2022 Dec 1. PMID: 36264563.
Ki67 as a Companion Diagnostic: Good or Bad News?Dowsett M, Nielsen TO, Rimm DL, Hayes DF. J Clin Oncol. 2022 Nov 20; 2022 Jul 11. PMID: 35816627.
Proceedings From the ASCO/College of American Pathologists Immune Checkpoint Inhibitor Predictive Biomarker Summit.Hayes DF, Herbst RS, Myles JL, Topalian SL, Yohe SL, Aronson N, Bellizzi AM, Basu Roy U, Bradshaw G, Edwards RH, El-Gabry EA, Elvin J, Gajewski TF, McShane LM, Oberley M, Philip R, Rimm DL, Rosenbaum JN, Rubin EH, Schlager L, Sherwood SW, Stewart M, Taube JM, Thurin M, Vasalos P, Laser J. JCO Precis Oncol. 2022 Nov. PMID: 36446042.
Location matters: LAG3 levels are lower in renal cell carcinoma metastatic sites compared to primary tumors, and expression at metastatic sites only may have prognostic importance.Schoenfeld DA, Merkin RD, Moutafi M, Martinez S, Adeniran A, Kumar D, Jilaveanu L, Hurwitz M, Rimm DL, Kluger HM. Front Oncol. 2022; 2022 Oct 13. PMID: 36313654.
The Quest to Eradicate HPV-Related Oropharyngeal Carcinoma: An Opportunity Not to Miss.Lalonde CS, Teng Y, Burtness BA, Ferris RL, Ahmed R, Saba NF. J Natl Cancer Inst. 2022 Oct 6. PMID: 35567531.
Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study.Acs B, Leung SCY, Kidwell KM, Arun I, Augulis R, Badve SS, Bai Y, Bane AL, Bartlett JMS, Bayani J, Bigras G, Blank A, Buikema H, Chang MC, Dietz RL, Dodson A, Fineberg S, Focke CM, Gao D, Gown AM, Gutierrez C, Hartman J, Kos Z, Lænkholm AV, Laurinavicius A, Levenson RM, Mahboubi-Ardakani R, Mastropasqua MG, Nofech-Mozes S, Osborne CK, Penault-Llorca FM, Piper T, Quintayo MA, Rau TT, Reinhard S, Robertson S, Salgado R, Sugie T, van der Vegt B, Viale G, Zabaglo LA, Hayes DF, Dowsett M, Nielsen TO, Rimm DL. Mod Pathol. 2022 Oct; 2022 Jun 21. PMID: 35729220.
Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer.Moutafi M, Robbins CJ, Yaghoobi V, Fernandez AI, Martinez-Morilla S, Xirou V, Bai Y, Song Y, Gaule P, Krueger J, Bloom K, Hill S, Liebler DC, Fulton R, Rimm DL. Lab Invest. 2022 Oct; 2022 May 20. PMID: 35595825.
Quantitative assessment of Siglec-15 expression in lung, breast, head, and neck squamous cell carcinoma and bladder cancer.Shafi S, Aung TN, Xirou V, Gavrielatou N, Vathiotis IA, Fernandez A, Moutafi M, Yaghoobi V, Herbst RS, Liu LN, Langermann S, Rimm DL. Lab Invest. 2022 Oct; 2022 May 17. PMID: 35581307.
STING Agonists in Head and Neck Squamous Cell Carcinoma.Wallington DG, Contessa JN, Hayman TJ. Cancer J. 2022 Sep-Oct 01. PMID: 36165729.
Integrating Targeted Therapies in the Management of Head and Neck Cancers.Burtness B. Cancer J. 2022 Sep-Oct 01. PMID: 36165719.
Clinical Outcomes and Immune Markers by Race in a Phase I/II Clinical Trial of Durvalumab Concomitant with Neoadjuvant Chemotherapy in Early-Stage TNBC.Foldi J, Kahn A, Silber A, Qing T, Reisenbichler E, Fischbach N, Persico J, Adelson K, Katoch A, Chagpar A, Park T, Blanchard A, Blenman K, Rimm DL, Pusztai L. Clin Cancer Res. 2022 Sep 1. PMID: 35903931.
Programmed Death-Ligand 1 and Programmed Death-Ligand 2 mRNAs Measured Using Closed-System Quantitative Real-Time Polymerase Chain Reaction Are Associated With Outcome and High Negative Predictive Value in Immunotherapy-Treated NSCLC.Fernandez AI, Gavrielatou N, McCann L, Shafi S, Moutafi MK, Martinez-Morilla S, Vathiotis IA, Aung TN, Yaghoobi V, Bai Y, Chan YG, Weidler J, Herbst R, Bates M, Rimm DL. J Thorac Oncol. 2022 Sep; 2022 Jun 25. PMID: 35764237.
Cemiplimab for Orbital Squamous Cell Carcinoma in 11 Cases.Steren B, Burtness B, Bhatia A, Demirci H, Shinder R, Yoo D, Tse B, Pointdujour-Lim R. Ophthalmic Plast Reconstr Surg. 2022 Sep-Oct 01; 2022 May 3. PMID: 35502804.
Not all well-differentiated cutaneous squamous cell carcinomas are equal: Tumors with disparate biologic behavior have differences in protein expression via digital spatial profiling.Vesely M, Martinez-Morilla S, Gehlhausen JR, McNiff JM, Whang PG, Rimm D, Ko CJ. J Am Acad Dermatol. 2022 Sep; 2022 Apr 6. PMID: 35398219.
The Effect of Tobacco Smoke N-Nitrosamines, NNK and NDEA, and Nicotine, on DNA Mismatch Repair Mechanism and miRNA Markers, in Hypopharyngeal Squamous Cell Carcinoma: An In Vivo Model and Clinical Evidence.Doukas SG, Vageli DP, Doukas PG, Nikitovic D, Tsatsakis A, Judson BL. Curr Oncol. 2022 Aug 4; 2022 Aug 4. PMID: 36005175.
Spatially resolved proteomic profiling identifies tumor cell CD44 as a biomarker associated with sensitivity to PD-1 axis blockade in advanced non-small-cell lung cancer.Moutafi MK, Molero M, Martinez Morilla S, Baena J, Vathiotis IA, Gavrielatou N, Castro-Labrador L, de Garibay GR, Adradas V, Orive D, Valencia K, Calvo A, Montuenga LM, Ponce Aix S, Schalper KA, Herbst RS, Paz-Ares L, Rimm DL, Zugazagoitia J. J Immunother Cancer. 2022 Aug. PMID: 36002182.
Objective assessment of tumor infiltrating lymphocytes as a prognostic marker in melanoma using machine learning algorithms.Aung TN, Shafi S, Wilmott JS, Nourmohammadi S, Vathiotis I, Gavrielatou N, Fernandez A, Yaghoobi V, Sinnberg T, Amaral T, Ikenberg K, Khosrotehrani K, Osman I, Acs B, Bai Y, Martinez-Morilla S, Moutafi M, Thompson JF, Scolyer RA, Rimm DL. EBioMedicine. 2022 Aug; 2022 Jul 7. PMID: 35810563.
Discovery of Biomarkers of Resistance to Immune Checkpoint Blockade in NSCLC Using High-Plex Digital Spatial Profiling.Moutafi M, Martinez-Morilla S, Divakar P, Vathiotis I, Gavrielatou N, Aung TN, Yaghoobi V, Fernandez AI, Zugazagoitia J, Herbst RS, Schalper KA, Rimm DL. J Thorac Oncol. 2022 Aug; 2022 Apr 28. PMID: 35490853.
Efficacy and toxicity of weekly paclitaxel, carboplatin, and cetuximab as induction chemotherapy or in cases of metastases or relapse for head and neck cancer with a focus on elderly or frail patients.Forman R, Deshpande H, Burtness B, Bhatia AK. Head Neck. 2022 Aug; 2022 Apr 30. PMID: 35488876.
Major Salivary Gland Cancer With Distant Metastasis Upon Presentation: Patterns, Outcomes, and Imaging Implications.Benchetrit L, Mehra S, Mahajan A, Rahmati RW, Judson BL, Edwards HA. Otolaryngol Head Neck Surg. 2022 Aug; 2021 Nov 16. PMID: 34784258.
Tumor immune microenvironment of self-identified African American and non-African American triple negative breast cancer.Marczyk M, Qing T, O'Meara T, Yagahoobi V, Pelekanou V, Bai Y, Reisenbichler E, Cole KS, Li X, Gunasekharan V, Ibrahim E, Fanucci K, Wei W, Rimm DL, Pusztai L, Blenman KRM. NPJ Breast Cancer. 2022 Jul 22; 2022 Jul 22. PMID: 35869114.
Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score.Burtness B, Rischin D, Greil R, Soulières D, Tahara M, de Castro G Jr, Psyrri A, Brana I, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesia R, Ngamphaiboon N, Rordorf T, Wan Ishak WZ, Ge J, Swaby RF, Gumuscu B, Harrington K. J Clin Oncol. 2022 Jul 20; 2022 Mar 25. PMID: 35333599.
Quantitative tissue analysis and role of myeloid cells in non-small cell lung cancer.Henick BS, Villarroel-Espindola F, Datar I, Sanmamed MF, Yu J, Desai S, Li A, Aguirre-Ducler A, Syrigos K, Rimm DL, Chen L, Herbst RS, Schalper KA. J Immunother Cancer. 2022 Jul. PMID: 35793873.
Practice Patterns Related to Mitigation of Neurocognitive Decline in Patients Receiving Whole Brain Radiation Therapy.Jairam V, Park HS, Yu JB, Bindra RS, Contessa JN, Jethwa KR. Adv Radiat Oncol. 2022 Jul-Aug; 2022 Mar 21. PMID: 35521071.
Development of an immunohistochemical assay for Siglec-15.Shafi S, Aung TN, Robbins C, Zugazagoitia J, Vathiotis I, Gavrielatou N, Yaghoobi V, Fernandez A, Niu S, Liu LN, Cusumano ZT, Leelatian N, Cole K, Wang H, Homer R, Herbst RS, Langermann S, Rimm DL. Lab Invest. 2022 Jul; 2022 Apr 22. PMID: 35459795.
Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer.Blenman KRM, Marczyk M, Karn T, Qing T, Li X, Gunasekharan V, Yaghoobi V, Bai Y, Ibrahim EY, Park T, Silber A, Wolf DM, Reisenbichler E, Denkert C, Sinn BV, Rozenblit M, Foldi J, Rimm DL, Loibl S, Pusztai L. Clin Cancer Res. 2022 Jun 13. PMID: 35377948.
Image analysis reveals molecularly distinct patterns of TILs in NSCLC associated with treatment outcome.Ding R, Prasanna P, Corredor G, Barrera C, Zens P, Lu C, Velu P, Leo P, Beig N, Li H, Toro P, Berezowska S, Baxi V, Balli D, Belete M, Rimm DL, Velcheti V, Schalper K, Madabhushi A. NPJ Precis Oncol. 2022 Jun 3; 2022 Jun 3. PMID: 35661148.